Related Experiment Video
Updated: Sep 13, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Germline and Somatic Changes Associated with the Development of Inherited and De Novo Pediatric Acute Myeloid
1Department of Pathology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Insights
Pediatric acute myeloid leukemia (AML) is mainly caused by gene rearrangements, not mutations. Understanding these genomic abnormalities is key for accurate laboratory diagnosis and improved patient survival rates.
Area of Science:
- Pediatric Oncology
- Genetics
- Hematology
Background:
- Acute myeloid leukemia (AML) represents 15-20% of childhood leukemia cases.
- Most pediatric AML arises de novo from in utero somatic mutations, while some result from inherited syndromes.
- Infant AML has a poorer prognosis compared to older children.
Purpose of the Study:
- To review common genomic abnormalities in pediatric AML.
- To characterize the laboratory detection methods for these abnormalities.
- To highlight the role of cytogenetics in diagnosing pediatric AML.
Main Methods:
- Review of existing literature on pediatric AML genomics.
- Analysis of laboratory diagnostic approaches for genomic abnormalities.
- Focus on cytogenomic analyses and gene sequencing.
Main Results:
- Pediatric AML is characterized by gene rearrangements more than gene mutations.
- Cytogenomic analyses are crucial for identifying key abnormalities.
- Detection methods vary based on the specific genomic alteration.
Conclusions:
- Genomic abnormalities, particularly gene rearrangements, are central to pediatric AML.
- Accurate laboratory detection through cytogenetics is vital for diagnosis and prognosis.
- Further research into specific genomic drivers can improve treatment strategies.
Abstract:
Acute myeloid leukemia (AML) accounts for only about 15-20% of pediatric leukemia and an overall incidence of 1.4 cases per 200,000 children under the age of 15 years. The majority of pediatric AML occurs de novo, often as the result of somatic first hits in utero. A minority of pediatric AML occurs in response to a predisposition syndrome, such as a bone marrow failure syndrome, or other inherited mutations and copy number changes. While the overall survival of pediatric patients with AML is approximately 70%, survival at the individual level is dependent on the abnormality detected either through cytogenomic analyses or sequencing for mutations in responsible genes. Indeed, de novo infant AML carries a more sobering prognosis than that of pediatric AML. This review describes many of the common genomic abnormalities associated with pediatric AML and characterizes their detection from a laboratory assessment perspective. Pediatric AML is primarily a disease of gene rearrangements rather than of gene mutations, and, as such, clinical cytogenetics takes a primary role.
More Related Videos
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
01:39Mutations
02:21Cancers Originate from Somatic Mutations in a Single Cell
01:15Differentiation of Common Myeloid Progenitor Cells
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Lineage Commitment
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...